Home › B-Cell Lymphoma › Texas › San Antonio
B-Cell Lymphoma clinical trials in San Antonio, TX
6 studies for B-Cell Lymphoma are looking for participants at sites in and around San Antonio (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RecruitingPhase 1
- Methodist Children's Hospital, San Antonio
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- Texas Transplant Institute, San Antonio
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RecruitingPhase 2
- Research Site, San Antonio
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- Texas Transplant Institute, San Antonio
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- Texas Transplant Institute, San Antonio
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 1/2
- SCRI, San Antonio
B-Cell Lymphoma trials in other cities
- New York City, NY17 studies
- Houston, TX16 studies
- Chicago, IL13 studies
- Nashville, TN12 studies
- Philadelphia, PA11 studies
- Rochester, MN10 studies
- Milwaukee, WI10 studies
- Boston, MA10 studies
- Baldwin Park, CA9 studies
- Cleveland, OH8 studies
- Salt Lake City, UT8 studies
- Seattle, WA8 studies
Other studies in San Antonio
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer45 studies
- Metastatic Cancer44 studies
- Colorectal Cancer43 studies
- Cancer (all types)41 studies
- Obesity39 studies
- Type 2 Diabetes37 studies
- Overweight34 studies
- Ovarian Cancer33 studies
- Pancreatic Cancer33 studies
- Lung Cancer27 studies
- Prostate Cancer27 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.